Orion Begins Phase 1 Trial of ODM-216, Its First Clinical Biologic
Orion has begun a Phase 1 trial of ODM-216, its first biologic drug to enter clinical development.
Related stories
Alamos Gold Posts Higher Q3 Adjusted Net Earnings YoY
Alamos Gold reported higher adjusted net earnings year over year for the third quarter.
M impact | EQUITY | Oct 29, 2026, 09:38 AM UTC
三六零 Says Q3 Revenue Fell 3.9% Year Over Year
M impact | EQUITY | Oct 29, 2026, 09:38 AM UTC
Linde Q3 Revenue Rises 9% on Higher Pricing and Volumes
M impact | EQUITY | Oct 29, 2026, 09:38 AM UTC
MGRC Reports Fiscal Q3 Profit and EPS
MGRC reported fiscal 2026 third-quarter profit attributable to shareholders, up 2.84% year over year, and basic EPS.
M impact | EQUITY | Oct 29, 2026, 09:37 AM UTC
ROG Reports Fiscal Q3 Profit Growth of 161.3%
ROG reported fiscal 2026 third-quarter profit attributable to shareholders up 161.3% year over year, with basic EPS also reported.
M impact | EQUITY | Oct 29, 2026, 09:37 AM UTC
PBI Reports Fiscal Q3 Profit and EPS
Profit attributable to shareholders rose 36.94% year over year; basic EPS was also reported.
M impact | EQUITY | Oct 29, 2026, 09:37 AM UTC